Ph.D., CEO, SolveBio
Mark is the CEO and co-founder of SolveBio, a rapidly growing technology company based in New York that is quickly becoming an indispensable strategic partner for Biopharma R&D in the precision medicine space. Mark received a PhD in Genetics from Stanford University, focusing on employing bioinformatics methodologies in the analysis of genomics data in oncology, and an AB in Biochemistry and Computer Science from Harvard University. Prior to his doctoral studies, Mark worked in research laboratories at MIT, Yale, and the Weizmann Institute.
Presentation Title and Company Description
Clinical Dx Showcase: Liquid Biopsy: Are your Clinical Trials Ready?
SolveBio is a strategic technology partner for pharma organizations adopting precision medicine in the clinical trial ecosystem. SolveBio’s team combines scientific expertise, software engineering competence, and proprietary technologies delivering solutions for Pharma’s most challenging problems in translational sciences and clinical development.